




BTOG Webinar: WCLC 2024 / ESMO 2024 Update

Monday 1st October 2024

18:00 – 19:30

Applied for 1 category 1 (external) CPD credit (reference 149911)

From the Federation of the Royal Colleges of Physicians of the United Kingdom

To join this event on 1st October, if you're not a BTOG member, please join for free at www.btog.org/join/. If already a BTOG member, just log in at <https://www.btog.org/signin/> on 1st October 2024 and you will be able to join the live event.

Chair: Dr Tom Newsom-Davis
BTOG Steering Committee Vice-Chair/Chair-Elect

This webinar will cover clinically impactful thoracic oncology highlights of WCLC 2024 and ESMO 2024.

Each 20 minutes presentation time

18:00	Introduction	Tom Newsom-Davis
18:05	WCLC 2024 Highlights	Martin Forster
18:25	ESMO 2024 Metastatic Disease Highlights	Meenali Chitnis
18:45	ESMO 2024 Early and Locally Advanced Disease Highlights	Yvonne Summers
19:05	Q&A and Panel	
19:30	Close	

Biographies

Dr Meenali Chitnis is a Consultant Medical Oncologist at The Oxford Cancer & Haematology Centre, where she specialises in treating lung and prostate cancer. Having graduated with Honours from St Bartholomew's and the Royal London School of Medicine and Dentistry in 2000, she undertook specialist oncology training in London and Oxford. She was awarded a Cancer Research UK Fellowship for her DPhil studies at the University Oxford, which focused on signalling pathways in cancer. Dr Chitnis is Departmental Lead for the Lung Cancer service in Oxford and is a member of the Thames Valley Strategic Clinical Network Lung Cancer Alliance group. Dr Chitnis is active in the field of research, recognising the importance of advancements in science in the care of her patients. She is the Oxford Lung Cancer research lead and is the Principal Investigator on a diverse portfolio of clinical trials. She is committed to improving patient pathways and access to the latest treatments and innovation.

Dr Martin Forster is an associate professor at UCL and consultant medical oncologist at University College Hospital. He specialises in thoracic and head and neck cancers and has a particular interest in drug development and in using the increasing understanding of cancer biology to design studies that distinguish patient populations most likely to gain benefit from new drugs and new drug combinations. He is a core member of the lung and head and neck cancer teams and runs a research-based practice, being principal investigator or chief investigator for over 50 early and late-phase clinical trials, from first-in-human to registration Phase III trials. These include targeted therapies in precision oncology trials, novel immunotherapies, and more recently solid cancer cell therapy studies. He collaborates broadly with national and international groups involved in translational research and is joint lead for the clinical trials theme of the Cancer Research UK Lung Cancer Centre of Excellence and chairs the NIHR Head and Neck Research Group. He is the UCLH clinical lead for chemotherapy services and co-lead for the London Cancer Chemotherapy Expert Reference Group.

Dr Tom Newsom-Davis: Steering Committee Vice Chair and Chair-Elect

Dr Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He has been a member of the BTOG Steering Committee for the past 2 years, and until recently was part of the National Cancer Research Institute Lung Group, and led the RM Partners Cancer Vanguard lung pathway.

Dr Newsom-Davis is actively involved in clinical research, and has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including BTOG, the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award. Tom is the BTOG representative on the UKLCC.

Dr Yvonne Summers studied undergraduate medicine at St Andrews University and moved to Manchester University in 1990 to complete her clinical training. Between 1997 and 2004 she trained in medical oncology at The Christie and during this period she was awarded a PhD for research in the field of stem cell biology at the Paterson Institute for Cancer Research (now the Cancer Research UK Manchester Institute). She took up her first consultant post at Belfast City Hospital in 2004 where she developed medical oncology services and clinical research for lung cancer patients. In 2009 she returned to Manchester to join the Lung Cancer Team at The Christie and the University Hospital of South Manchester. Her interests are in clinical trials focusing on drug development of targeted agents and immunotherapy for patients with lung cancer and she is chief investigator and principal investigator on a portfolio of lung cancer clinical trials. She is a member of the EORTC lung group, the NCRI lung clinical studies group (CSG), the lung cancer clinical reference group (CRG) and represents the RCP at lung cancer NICE technology appraisals.